Effects of pulmonary arterial hypertension-targeted therapy on World Health Organization (WHO)/New York Heart Association (NYHA) functional class, exercise capacity and haemodynamics at first follow-up visit in patients with severe sarcoidosis-associated pulmonary hypertension#
| Baseline | First follow-up visit¶ | Difference | p-value | |
| WHO/NYHA functional class I–II/III/IV | 11/52/18 | 26/45/10 | 0.01 | |
| 6MWD m | 311±127 | 324±138 | +13 m | 0.33 |
| RAP mmHg | 7±4 | 6±4 | −14% | 0.007 |
| mPAP mmHg | 48±9 | 42±11 | −13% | <0.00001 |
| Cardiac index L·min−1·m−1 | 2.6±0.8 | 2.9±0.8 | +12% | <0.00001 |
| PVR Wood units | 9.7±4.4 | 6.9±3.0 | −29% | <0.00001 |
Data are expressed as n or mean±sd, unless otherwise stated. 6MWD: 6-min walk distance; RAP: right atrial pressure; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance. #: n=81; ¶: median (interquartile range) 4.5 (4.0–6.7) months.